Table 5.
Hazard ratios and 95% confidence intervals of reported cardiac conditions by treatment*
| Congestive heart failure | Myocardial infarction | Pericardial disease | Valvular abnormalities | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||||
| Gender | |||||||||||
| Male | 1.0† | — | 1.0† | — | 1.0† | — | 1.0† | — | |||
| Female | 1.4 (1.1 to 1.9) | 0.018 | 0.6 (0.4 to 0.9) | 0.014 | 1.3 (0.9 to 1.8) | 0.15 | 1.6 (1.2 to 2.1) | 0.003 | |||
| Age at diagnosis | |||||||||||
| 0-4 years | 3.9 (2.1 to 7.3) | <0.001 | 1.0 (0.4 to 3.0) | 0.96 | 1.8 (0.9 to 3.8) | 0.13 | 2.7 (1.4 to 5.3) | 0.004 | |||
| 5-9 years | 2.3 (1.3 to 4.0) | 0.004 | 1.9 (0.9 to 4.0) | 0.090 | 1.3 (0.7 to 2.5) | 0.44 | 2.5 (1.5 to 4.3) | 0.001 | |||
| 10-14 years | 1.2 (0.8 to 1.9) | 0.37 | 0.8 (0.4 to 1.5) | 0.49 | 0.8 (0.5 to 1.3) | 0.41 | 1.5 (1.0 to 2.2) | 0.050 | |||
| 15-20 years | 1.0† | — | 1.0† | — | 1.0† | — | 1.0† | — | |||
| Treatment era | |||||||||||
| 1970-4 | 1.0† | — | 1.0† | — | 1.0† | — | 1.0† | — | |||
| 1975-9 | 1.1 (0.7 to 1.7) | 0.60 | 2.1 (1.2 to 3.8) | 0.010 | 1.5 (1.0 to 2.4) | 0.078** | 1.4 (1.0 to 2.0) | 0.090** | |||
| 1980-6 | 1.9 (1.2 to 3.0) | 0.008 | 2.2 (1.1 to 4.3) | 0.023 | 1.4 (0.8 to 2.4) | 0.25 | 1.8 (1.2 to 2.9) | 0.008 | |||
| Average cardiac radiation dose§ | |||||||||||
| No cardiac radiation | 1.0† | — | 1.0† | — | 1.0† | — | 1.0† | — | |||
| <500 cGy | 0.9 (0.6 to 1.4) | 0.75 | 0.7 (0.4 to 1.4) | 0.36 | 0.7 (0.4 to 1.1) | 0.11 | 0.6 (0.4 to 1.0) | 0.063 | |||
| 500 to <1500 cGy | 1.3 (0.7 to 2.5) | 0.43 | 0.6 (0.1 to 2.5) | 0.45 | 1.9 (0.9 to 3.9) | 0.077 | 1.4 (0.7 to 2.9) | 0.40 | |||
| 1500 to <3500 cGy | 2.2 (1.4 to 3.5) | <0.001 | 2.4 (1.2 to 4.9) | 0.011 | 2.2 (1.3 to 3.9) | 0.005 | 3.3 (2.1 to 5.1) | <0.001 | |||
| ≥3500 cGy | 4.5 (2.8 to 7.2) | <0.001 | 3.6 (1.9 to 6.9) | <0.001 | 4.8 (2.8 to 8.3) | <0.001 | 5.5 (3.5 to 8.6) | <0.001 | |||
| Chemotherapy | |||||||||||
| Anthracycline v none¶ | |||||||||||
| <250 mg/m2 | 2.4 (1.5 to 3.9) | <0.001 | 1.3 (0.6 to 2.8) | 0.50 | 1.6 (0.9 to 2.9) | 0.13 | 1.4 (0.8 to 2.3) | 0.25 | |||
| ≥250 mg/m2 | 5.2 (3.6 to 7.4) | <0.001 | 1.1 (0.5 to 2.1) | 0.87 | 1.8 (1.1 to 3.0) | 0.020 | 2.3 (1.6 to 3.3) | <0.001 | |||
| Cisplatin v none | 1.7 (0.9 to 2.9) | 0.062 | ‡ | — | ‡ | — | ‡ | — | |||
| Vincristine v none | ‡ | — | 0.7 (0.4 to 1.1) | 0.081 | ‡ | — | ‡ | — | |||
| Bleomycin v none | ‡ | — | ‡ | — | 1.6 (0.9 to 2.9) | 0.091 | ‡ | — | |||
| Cyclophosphamide v none | ‡ | — | ‡ | — | 1.5 (1.0 to 2.3) | 0.049** | ‡ | — | |||
*Estimates adjusted for all variables in the table as well as race, household income, education, and tobacco use.
†Reference group.
‡Not included in model.
§Test for trend (P value)-all outcomes (<0.001).
¶Test for trend (P value)-congestive heart failure (<0.001), myocardial infarction (0.8), pericardial disease (0.03), valvular disease (<0.001).
**Not significant at P=0.05.